Human Health and Exposure Monitoring Teams

The LRI Health Effects Monitoring Team (HEMT) oversees LRI programme development and progress in funded research on chemical carcinogenicity, chemical allergy, neurodevelopmental disorders in children, the development of alternative approaches in mammalian toxicity testing, and new areas like epigenetics and human health effects of nanomaterials.

The current research portfolio under the health and exposure programme looks as follows with projects starting in 2017 marked below with *:

  • AIMT2: Mechanism-based characterisation of systemic toxicity for RepDose database substances employing in vitro toxicogenomics
    Principal investigator: Dr. Rob H Stierum, TNO, AJ Zeist, The Netherlands
  • AIMT3: Data-integration for endpoints, cheminformatics and omics
    Principal investigator: Dr. Joost van Delft, Maastricht University, The Netherlands
  • AIMT4*: Moving from DECO towards OECD
    Principal investigator: Dr Danyel Jennen, Maastricht University (UM), Maastricht, The Netherlands
  • AIMT5*: AOP/MOA of Developmental Ontology
    Request for Proposals (RfP) advertised in 2014. Selection Team meeting held in February 2015
  • AIMT6*: CON4EI: CONsortium for in vitro Eye Irritation testing strategy
    Principal investigator: Dr An Van Rompay, Flemish Institute for Technological Research (VITO), Belgium
  • B6: A toxicogenomic approach to enhance the specificity and predictive value of the murine local lymph node assay
    Principal investigator: Dr. Darrell Boverhof, Dow, Midland, MI, USA
  • B7: Determining the nature of chemical substance additively from household consumer products
    Principal investigator: Dr. Natalie von Götz, ETH, Safety and Environmental Technology Group, Zürich, Switzerland (Final report delivered in January 2014)
  • B9: Characterising the nature of dermal exposure from consumer products and articles
    Principal investigator: Ir. Rudi Torfs, VITO (Flemish Institute for Technological Research), Mol, Belgium
  • B10: Animal and human NOAELs: cross-species comparison, inference and synthesis
    Principal investigator: Dr. Lesley Rushton, Imperial College London, UK (Final report delivered in April 2014)
  • B11: Integrated external and internal exposure modelling platform
    Principal investigator: Assoc. Prof. Dimosthenis Sarigiannis, Centre for Research and Technology Hellas, Thessaloniki, Greece
  • B12*: Assessing the relevance of the dust contribution to substances from consumer products and articles
    Principal investigator: Dr. Natalie von Götz, ETH, Safety and Environmental Technology Group, Zürich, Switzerland
  • B13: Development of a mechanistic in silico multi-scale framework to assess dermal absorption of chemicals
    Principal investigator: Prof. Gerald Kasting – University of Cincinnati, OH, USA
  • B14*: Skin Sensitisation – Chemical Applicability Domain of the Local Lymph Node Assay (LLNA)
    Principal investigator: A-M Api – RIFM, NJ, USA
  • B15: Developing a robust method of allocating efficiency measures to regulatory instruments in the chemicals industry
    Principal investigator: L Levy – Cranfield University, UK
  • B16*: External validation of Tier-1 workers dermal exposure estimates in ECETOC TRA. Request for Proposals (RfP) advertised in 2014. Selection Team meeting held in February 2015
  • C3*: A comprehensive Epigenomic profile of liver tissue from Rat and Mouse
    Principal investigator: Prof. Richard Meehan, University of Edinburgh, UK
  • EMSG57: Endocrine disruptors and obesity, diabetes and heart disease: State of the science and biological plausibility
    Principal investigator: Dr. Judy LaKind, LaKind Associates, Catonsville, MD, USA
  • EMSG58*: Human adverse health effects of endocrine active substances: assessment of the quality of individual epidemiological studies and of the overall mechanistic and epidemiologic evidence
    Principal investigator: Prof. Carlo La Vecchia, IRCCS – Istituto di Ricerche Farmacologiche Mario Negri (IRFMN), Milan, Italy
  • HBM4: Understanding inter- and intra-individual variability in HBM spot samples
    Principal investigator: Dr. Ir. Roel Smolders, VITO (Flemish Institute for Technological Research), Mol, Belgium. (Final report delivered in 2014)
  • N1: Tiered approach to testing and assessment of nanomaterial safety to human health
    Principal investigator: Dr. Otto Creutzenberg, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
  • N3: Towards standardized testing guidelines (reproductive toxicity) relevant to nanomaterials
    Principal investigator: Dr. J.J.M (Han) Van de Sandt, TNO, AJ Zeist, The Netherlands
  • N4*: Science-based grouping of nanoparticles for industrial application of safe-by-design
    Principal investigator: Dr. ir. Hans Bouwmeester, RIKILT- Wageningen University and Research Center, Wageningen, The Netherlands
  • N5*: Biokinetics and long-term effects of inhaled nanoparticles
    Request for Proposals (RfP) advertised in 2014. Selection Team meeting held in February 2015